Catabasis Phase 3 PolarisDMD Trial for Edasalonexent Update & Additional Trial Sites Open for Enrollment
Catabasis Pharmaceuticals shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne. PolarisDMD clinical trial…Learn More